Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy-Reference-Cited by-同舟云学术

Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy

Published:2020-08-27 Issue:11 Volume:22 Page:
ISSN:1523-3790
Container-title:Current Oncology Reports
language:en
Short-container-title:Curr Oncol Rep

Author:

Mushti Sirisha L.^ORCID,Mulkey Flora,Tang Shenghui,Singh Harpreet,Lemery Steven J.,Goldberg Kirsten B.,Sridhara Rajeshwari,Keegan Patricia,Kluetz Paul G.,Pazdur Richard,Theoret Marc R.,Beaver Julia A.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11912-020-00974-z.pdf

Reference82 articles.

1. Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36(17):1675–84. https://doi.org/10.1200/jco.2017.77.0412.

2. Drugs@fda [database on the Internet]. U.S Food and Drug Administration. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed: March, 2020.

3. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33(31):3541–3. https://doi.org/10.1200/jco.2015.61.6870.

4. Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, et al. Novel patterns of response under immunotherapy. Ann Oncol. 2019;30(3):385–96. https://doi.org/10.1093/annonc/mdz003.

5. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progressive Disease with Mixed Response After Immunotherapy in Non-Small Cell Lung Cancer;Journal of Inflammation Research;2024-09

2. Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment;Cancer Letters;2024-08

3. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition;Cancers;2023-06-30

4. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study;Liver International;2023-01-13

5. Novel evidence for the prognostic impact of β-blockers in solid cancer patients receiving immune checkpoint inhibitors;International Immunopharmacology;2022-12